129 related articles for article (PubMed ID: 3681384)
1. Intracarotid infusion of PCNU (NSC: 95466): preclinical toxicological study in dogs.
Goumnerova L; Richard MT; Addison D; Montpetit V; Stewart DJ
J Neurooncol; 1987; 5(3):205-9. PubMed ID: 3681384
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of intracarotid PCNU.
Stewart DJ; Grahovac Z; Russel NA; Hugenholtz H; Gupta S; Benoit BC; Richard MT; Maroun JA; Hopkins HS; Locke L
J Neurooncol; 1987; 5(3):245-50. PubMed ID: 3681387
[TBL] [Abstract][Full Text] [Related]
3. Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs.
Wright KC; Stephens LC; Wallace S; Savaraj N; Feun LG
Chemotherapy; 1987; 33(6):437-44. PubMed ID: 3428010
[TBL] [Abstract][Full Text] [Related]
4. PCNU: a new nitrosourea in clinical oncology.
Poster DS; Penta JS; Bruno S
Am J Clin Oncol; 1982 Feb; 5(1):9-12. PubMed ID: 7081143
[TBL] [Abstract][Full Text] [Related]
5. The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.
Drewinko B; Yang LY
Invest New Drugs; 1983; 1(3):197-202. PubMed ID: 6678867
[TBL] [Abstract][Full Text] [Related]
6. CCNU (NSC-79037): preclinical toxicologic evaluation of a single intravenous infusion in dogs and monkeys.
Schaeppi U; Fleischman RW; Phelan RS; Ethier MF; Luthra YK
Cancer Chemother Rep 3; 1974 Sep; 5(1):53-64. PubMed ID: 4213020
[No Abstract] [Full Text] [Related]
7. Report of vascilitis and blindness after intracarotid injection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in dogs.
DeWys WD; Fowler EH
Cancer Chemother Rep; 1973 Feb; 57(1):33-40. PubMed ID: 4704100
[No Abstract] [Full Text] [Related]
8. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A.
Hiesiger EM; Green SB; Shapiro WR; Burger PC; Selker RG; Mahaley MS; Ransohoff J; VanGilder JC; Mealey J; Robertson JT
J Neurooncol; 1995; 25(2):143-54. PubMed ID: 8543970
[TBL] [Abstract][Full Text] [Related]
9. [Ocular complications of intracarotid chemotherapies with nitrosourea agents].
Rigal-Sastourne JC; Bidaux F; Mir F; Crepy P; Lucas B; Renard JP; Derosier C; Maurin JF; Bourgeois H
J Fr Ophtalmol; 1993; 16(5):304-10. PubMed ID: 8331249
[TBL] [Abstract][Full Text] [Related]
10. PCNU and recurrent childhood brain tumors.
Allen JC; Hancock C; Walker R; Tan C
J Neurooncol; 1987; 5(3):241-4. PubMed ID: 3681386
[TBL] [Abstract][Full Text] [Related]
11. Ocular complication of combined intracarotid chemotherapy and osmotic blood-brain barrier disruption.
Suda K; Nakasu S; Saito A
Nihon Geka Hokan; 1985 Sep; 54(5):359-63. PubMed ID: 3938210
[No Abstract] [Full Text] [Related]
12. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.
Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ
J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602
[TBL] [Abstract][Full Text] [Related]
13. An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
Weinkam RJ; Dolan ME
J Med Chem; 1983 Nov; 26(11):1656-9. PubMed ID: 6226795
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of 1-(2-chloroethyl)-3-(2,6-dioxo-(piperidyl)-1 nitrosourea (PCNU)(NSC-95466) in patients with advanced carcinoma of the lung.
Ratanatharathorn V; Samson MK; Haas CD; Cummings GD; O'Connor EJ; Baker LH
Am J Clin Oncol; 1983 Feb; 6(1):99-102. PubMed ID: 6837509
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein JR; Karlin DA; Bennetts RW; Stewart DJ; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):49-52. PubMed ID: 6837507
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic effects of 13 nitrosoureas on the LSA lymphoma ascites tumor of the C57BL mouse.
Feola JM; Maruyama Y
Oncology; 1986; 43(6):378-84. PubMed ID: 3808571
[TBL] [Abstract][Full Text] [Related]
17. Carcinogenicity of alkylating cytostatic drugs in animals.
Berger MR
IARC Sci Publ; 1986; (78):161-76. PubMed ID: 3583389
[No Abstract] [Full Text] [Related]
18. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological disposition of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in mice.
Rahman A; Luc PV; Schein PS; Woolley PV
Cancer Res; 1984 Jan; 44(1):149-53. PubMed ID: 6690033
[TBL] [Abstract][Full Text] [Related]
20. Functional and chemical markers of PCNU activity.
Kanter PM; Schwartz HS; West CR
Cancer Drug Deliv; 1983; 1(1):11-20. PubMed ID: 6544115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
